Specification
Description
This orthogonally-protected ornithine derivative is based on the hindered Dde variant ivDde. The side-chain ivDde group is considerably more stable to piperidine than Dde and is less prone to migrate from protected to unprotected side-chains. When removing ivDde in the presence of allyl-based protecting groups, allyl alcohol should be included in the deprotection solution to prevent reduction of the allyl group.
Synonyms
Fmoc-Orn(ivDde)-OH, N-α-Fmoc-N-δ-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl-L-ornithine
InChI
1S/C33H40N2O6/c1-20(2)16-27(30-28(36)17-33(3,4)18-29(30)37)34-15-9-14-26(31(38)39)35-32(40)41-19-25-23-12-7-5-10-21(23)22-11-6-8-13-24(22)25/h5-8,10-13,20,25-26,34H,9,14-19H2,1-4H3,(H,35,40)(H,38,39)/t26-/m0/s1
InChI Key
XSDVRBYPXOEYHM-SANMLTNESA-N
Application
Peptide synthesis.
Assay
≥85.0% (acidimetric)
≥98% (TLC)
≥98.0% (HPLC)
Reaction Suitability
reaction type: Fmoc solid-phase peptide synthesis
Storage Temperature
15-25℃